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Oxaliplatin induces hyperexcitability at motor and autonomic
neuromuscular junctions through effects on voltage-gated
sodium channels
*,1Richard G. Webster, 2Keith L. Brain, 3Richard H. Wilson, 3Jean L. Grem & 1Angela Vincent
1Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS; 2University
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT and 3Center for Cancer Research,
National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
1 Oxaliplatin, an effective cytotoxic treatment in combination with 5-fluorouracil for colorectal
cancer, is associated with sensory, motor and autonomic neurotoxicity. Motor symptoms include
hyperexcitability while autonomic effects include urinary retention, but the cause of these side-effects
is unknown. We examined the effects on motor nerve function in the mouse hemidiaphragm and on
the autonomic system in the vas deferens.
2 In the mouse diaphragm, oxaliplatin (0.5mM) induced multiple endplate potentials (EPPs)
following a single stimulus, and was associated with an increase in spontaneous miniature EPP
frequency. In the vas deferens, spontaneous excitatory junction potential frequency was increased
after 30min exposure to oxaliplatin; no changes in resting Ca2þ concentration in nerve terminal
varicosities were observed, and recovery after stimuli trains was unaffected.
3 In both tissues, an oxaliplatin-induced increase in spontaneous activity was prevented by the
voltage-gated Naþ channel blocker tetrodotoxin (TTX). Carbamazepine (0.3mM) also prevented
multiple EPPs and the increase in spontaneous activity in both tissues. In diaphragm,
b-pompilidotoxin (100mM), which slows Naþ channel inactivation, induced multiple EPPs similar
to oxaliplatin’s effect. By contrast, blockers of Kþ channels (4-aminopyridine and apamin) did not
replicate oxaliplatin-induced hyperexcitability in the diaphragm.
4 The prevention of hyperexcitability by TTX blockade implies that oxaliplatin acts on nerve
conduction rather than by effecting repolarisation. The similarity between b-pompilidotoxin and
oxaliplatin suggests that alteration of voltage-gated Naþ channel kinetics is likely to underlie the acute
neurotoxic actions of oxaliplatin.
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Introduction
Oxaliplatin (trans-1-diaminocyclohexane oxaliplatinum) is a
widely used and effective treatment in combination with
5-fluorouracil for colorectal cancer. Its efficacy was first
demonstrated in the metastatic setting (for review, see
Cvitkovic & Bekradda, 1999; Wiseman et al., 1999; Misset
et al., 2000). It has recently been shown to improve disease-free
survival (although not overall survival) in the adjuvant
treatment of colorectal cancer (Andre et al., 2004). Although
it has a good safety profile, its use is associated with sensory,
motor and autonomic neurotoxicity. A common neurotoxic
manifestation is motor neuron hyperexcitability (Wilson et al.,
2002), with spasms, myotonia and fasciculations of the limb
and jaw muscles occurring during and for a period of hours
after drug infusion (Raymond et al., 1998). Autonomic
manifestations of oxaliplatin toxicity are not so common
(Quasthoff & Hartung, 2002), but atonic bladder has been
reported (Taieb et al., 2002). Acute sensory neurotoxicity
includes parasthesiae, cold-induced dysasthesia, reversible
visual field changes and pharyngolaryngodysesthesias (Wilson
et al., 2002). The acute neurotoxicity associated with
oxaliplatin treatment is distinct from the chronic sensory
neurotoxicic action on the dorsal root ganglia, which is
associated with long-term treatment with a variety of platinum
analogues (Meijer et al., 1999), which produces a chronic
sensory neuropathy with parasthesia and sensory loss (Extra
et al., 1998). The central nervous system is relatively protected
from the toxic effects of the platinates, probably because of
their poor permeability through the blood–brain barrier,
although occasionally central neurotoxicity (such as ototoxi-
city) does occur (Extra et al., 1998).
The acute symptoms of oxaliplatin treatment are often
exacerbated by exposure to cold temperatures, and may
respond to some extent to antiepileptic drugs such as
carbamazepine (Lersch et al., 2002), but the relief of symptoms
is not always evident (Wilson et al., 2002). It is important that*Author for correspondence: E-mail: richard.webster@imm.ox.ac.uk
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we understand more about the molecular mechanisms by
which oxaliplatin affects the function of the peripheral nervous
system to provide a rational approach for prevention or
treatment of neurotoxicity. Oxaliplatin has been shown to alter
Naþ channel properties in cultured dorsal unpaired median
neurons from cockroach (Grolleau et al., 2001), rat peripheral
sensory nerve preparations and cultured dorsal root ganglia
cells (Adelsberger et al., 2000). Oxaliplatin has also been
shown to modify intracellular Ca2þ handling within the cell
bodies of cultured neurons (Grolleau et al., 2001). Either of
these mechanisms could occur in the peripheral nervous
system, but there have been no direct studies of peripheral
neuromuscular or autonomic transmission.
The mouse phrenic nerve/diaphragm preparation allows
investigation of both spontaneous and nerve-evoked release of
acetylcholine at the neuromuscular junction and is the site of
action of many drugs and toxins that increase motor nerve
excitability. The mouse vas deferens is densely innervated by
sympathetic nerves (Taxi, 1965) that release noradrenaline and
ATP (Burnstock, 1976), making it a useful preparation for the
selective investigation of sympathetic transmission. Although
autonomic pathology is rare, this preparation allows one to
study regulation of intracellular Ca2þ (Brain & Bennett, 1997;
O’Connor et al., 1999; Brain et al., 2001; Jackson et al., 2001),
which has not been achieved so far at the mature mammalian
skeletal neuromuscular junction. In this study, therefore, we
investigated the acute in vitro effects of oxaliplatin on
transmission in the mouse diaphragm by intracellular record-
ings of spontaneous miniature endplate potentials (MEPPs)
and nerve-evoked EPPs, and on changes in the vas deferens
by intracellular recordings and measurement of intraterminal
Ca2þ . We compared the findings with those in the presence of
a variety of drugs and toxins that alter nerve excitability.
Methods
Mouse preparations
For the phrenic nerve hemidiaphragm preparation, adult C57/
BL6 mice were killed by exposure to a raised CO2 atmosphere
followed by cervical dislocation. Phrenic nerve/hemidiaph-
ragm preparations were dissected from mouse thorax and
bathed in Krebs solution, bubbled with 95%O2/5%CO2.
Preparations were pinned out in a Sylgard-coated Petri dish
containing bubbled Krebs solution. Preparations were allowed
at least 30min of equilibration before commencement of
experimental procedures. For the vas deferens preparations,
8–12-week-old Balb/c mice (Harlan, U.K.) were killed by
cervical fracture and both vasa deferentia removed. The
connective tissue around each vas deferens was carefully
dissected in order to obtain clear images and to remove any
ganglia or isolated nerve cell bodies located close to the vas
deferens.
Solution and drugs
The bath solution (Krebs) for dissection and recording was
of the following composition (in mM): NaCl 118, KCl 4.7,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 24.9, Glucose 10, CaCl2
2.5. The following drugs (source) were made as stock solutions
at the stated (concentration) in distilled H2O and stored frozen
in aliquots until required, then added to Krebs to reach the
required concentration: m-conotoxin GIIIB (Peptide Institute,
Japan) (0.1mM); excipient-free oxaliplatin (kind gift of Sanofi
Synthelabo) (15mM); b-pompilidotoxin (Tocris Cookson Ltd,
U.K.) (10mM); tetrodotoxin (TTX) (Sigma-Aldrich Company
Ltd, Dorset, U.K.) (3mM); 4-aminopyridine (4-AP) (Sigma)
(100mM); apamin (Sigma) (1mM). carbamazepine (Sigma) was
dissolved in bubbled Krebs at the required concentration and
stirred vigorously until just prior to use.
Phrenic nerve hemidiaphragm preparation
The phrenic nerve was stimulated via a suction electrode
coupled to a pulse generator (GRASS instruments S48, solid-
state square wave stimulator, Quincy, U.S.A.) with an
associated stimulus isolation unit. To enable measurement of
evoked potentials, the muscle action potential and contraction
were blocked with 2.5mM m-conotoxin GIIIB. Neuromuscular
transmission viability was checked before contractile blockade.
Recordings were made at room temperature (20–221C) via
an Axoclamp-2A amplifier (Axon Instruments, Union City,
CA, U.S.A.).
Nerve-evoked EPPs and spontaneous EPPs (MEPPs) were
recorded intracellularly with conventional borosilicate glass
electrodes filled with 3M KCl (10–15MO resistance; Harvard
Apparatus, Edenbridge, Kent, U.K.) and filtered at 1 kHz.
Electrodes were positioned above endplate regions, as visua-
lised with a stereomicroscope, under micromanipulator con-
trol. Impalement adjacent to an endplate was indicated by a
fast EPP rise time (less than 2ms).
To evoke an EPP the nerve was stimulated supramaximally
with platinum wire electrodes. Upon impalement, a 30 s period
of equilibration was allowed before MEPP recordings began.
If the membrane potential drifted by more than 5mV or
depolarised below 55mV the recording from that endplate
was abandoned. Data signals were passed through a ‘Humbug
50Hz noise eliminator’ (Quest Scientific via Digitimer,
Welwyn Garden City, U.K.) to reduce electrical noise on
recordings. MEPPs were autodetected with Winwcp software
(Whole cell program, Strathclyde University, U.K.); auto-
detection was set such that all MEPPs with amplitude greater
than the magnitude of the residual electrical noise were
detected. Up to 30MEPPs followed by up to 30EPPs
(stimulated at 1Hz) were recorded per endplate for later
offline analysis. MEPP frequency was determined by two
methods, either by recording the time between detected events
(detected) or counting events over a longer time course
recording (direct).
Data analysis
Recorded MEPPs and EPPs were digitised at 12.5 kHz (CED
1401 interface, Cambridge Electronic Design, Cambridge,
U.K.) and stored on computer hardware. Each MEPP and
EPP was visually inspected and rejected if of poor quality or if
noise was autodetected. Records were analysed with Winwcp
software or pClamp 9 programs (Axon Instruments, Union
City, CA, U.S.A.). All MEPP and EPP amplitudes were
standardised to a resting membrane potential of 80mV to
correct for changes in driving force due to altered postjunc-
tional membrane potential (Katz & Thesleff, 1957). Mean
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quantal content was calculated by the direct method as
described previously (Giovannini et al., 2002).
Mouse vas deferens
Conventional intracellular recording techniques were used to
record excitatory junction potentials (EJPs) in smooth muscle
cells (see Brock & Cunnane, 1992). Each vas deferens was
superfused with physiological salt solution (PSS) containing:
NaCl 118.4, NaHCO3 25, NaH2PO4 1.13, KCl 4.7, CaCl2 1.8,
MgCl2 1.3 and glucose 11.1. The pH was maintained at 7.4,
and the solution oxygenated, by continuously bubbling with
95% O2/5% CO2. Oxaliplatin was applied by swapping the
perfusion solution to one containing 0.5mM oxaliplatin.
Stimuli (rectangular pulses, 0.01ms duration, amplitude
10V) were delivered through Ag/AgCl electrodes positioned
around the proximal end of the vas deferens. Microelectrodes
were filled with 5M potassium acetate and had tip resistances
of 40–80MO.
Intracellular recordings were acquired with a PowerLab 4SP
(ADInstruments Ltd, Chalgrove Oxon, U.K.) attached to a
Macintosh computer running Chart v.4.2 (ADInstruments).
Data analysis was performed offline and automated using
custom-written macros. Spontaneous excitatory junction
potentials (sEJPs) were detected using the ‘template’ extension;
this algorithm correlates a rolling, normalised segment of
the trace with a user-selected template (a typical sEJP). A
correlation of 40.9 was used to define the occurrence of
an sEJP; only sEJPs with an amplitude of 41mV were
counted. The sensitivity and specificity of this technique
(compared to manual counting) were greater than 0.9. A burst
of sEJPs is arbitrarily defined as three sEJPs within 1 s.
Confocal microscopy
The cut prostatic end of the vas deferens was secured in a glass
micropipette containing the Ca2þ indicator Oregon Green 488
BAPTA-1, 10 kDa dextran (Oregon-BAPTA-1; Molecular
Probes, OR, U.S.A.), using a protocol previously described
(Brain & Bennett, 1997). The preparation was left for 5 h at
room temperature, then removed from the pipette and washed
in Krebs for a further 5 h. The vas deferens was placed in a
chamber that was continuously perfused with PSS (bath
temperature 31–321C). The base of the chamber was a
coverslip; images were acquired with a Leica NT inverted
confocal microscope. Field stimuli (pulse width 0.6ms;
amplitude 10V) were applied with parallel platinum electrodes
located near the prostatic end of the vas deferens; stimuli were
synchronised with the start of image acquisition, so that the
interval between each stimulus and recording was fixed.
A total of 128, 256 256 pixel images were acquired at the
fastest possible speed (4.67Hz) every 3min. Field stimuli were
triggered on the 56th–60th frames, inclusive (i.e. five impulses
at about 5Hz).
Image analysis
Image analysis was performed with NIH Image version 1.63
(from http://rsb.info.nih.gov/nih-image/). The fluorescent in-
tensity in individual nerve terminal varicosities was measured,
accounting for any movement of the preparation, using
custom-written macros as previously described (Brain &
Bennett, 1997).
Statistics and data handling
Values are expressed as mean7s.e.m., and statistical analysis
was performed with InStat software (GraphPad Software,
Inc., San Diego, CA, U.S.A.), a P-value of 40.05 was
considered to demonstrate the lack of a significant difference
between groups. It is assumed that each nerve terminal
varicosity or endplate behaves independently. The kinetics of
Ca2þ recovery in nerve terminal varicosities following nerve
stimulation was modelled as the sum of two exponentials,
using GraphPad Prism (GraphPad Software Inc.).
Results
Effects of oxaliplatin on neuromuscular transmission
in the mouse diaphragm
Recordings from independent endplates were made as
frequently as possible (usually every 2–5min). Spontaneous
MEPP amplitude, MEPP frequency, EPP amplitude and
quantal content remained relatively constant for over 70min
when only vehicle (66 ml H2O in 2ml Krebs) or oxalic acid, a
metabolite of oxaliplatin (final concentration, 0.5mM) were
added to the incubation (Table 1 and Figure 1a).
Oxaliplatin (0.5mM) had no immediate effect on neuro-
transmission. However, after an average of 37.171.7min
(n¼ 10 preparations), changes began to be observed
(Figure 1b). Double responses to single stimuli appeared but,
in this early phase, not every stimulus evoked a multiple
response (Figure 1bi, ii). At this stage, EPP amplitudes and
MEPP amplitudes (Table 1 and Figure 1biii) were no different
from control. However, in the continued presence of oxalipla-
tin, the evoked potentials became increasingly abnormal with
trains of potentials evoked by a single stimulus (Figure 1ci, ii).
Eventually, 20–30min after the initial changes, EPPs were
unattainable following stimulation at some endplates; while
at others spontaneous activity was very frequent (Figure 1ciii)
and individual EPPs could not be evoked by stimulation.
If oxaliplatin was washed out after the late phase had begun,
disruption of neurotransmission was not reversed.
MEPPs were not altered in amplitude or frequency during
the preliminary incubation in oxaliplatin, and were normal in
amplitude and frequency during the early phase when multiple
EPPs began to appear (Table 1). However, during the late
phase, when trains of EPPs were evoked by single stimuli,
MEPP frequency was significantly increased (Figure 1d and
Table 1). During runs of overlapping MEPPs, EPPs could
sometimes not be evoked upon stimulation.
Interestingly, MEPP frequency elevation by oxaliplatin was
not observed when the tissue was left unstimulated during
80min of oxaliplatin incubation (Figure 2a; Table 2), but a
single stimulus at 80min resulted in a massive production of
overlapping MEPPs (Figure 2b), suggesting that oxaliplatin is
able to change the underlying motor nerve function in the
absence of nerve stimulation, although its effects are not seen
until nerve stimulation occurs. When stimulated after 80min in
oxaliplatin without stimulation, neither single EPPs nor trains
of EPPs could be evoked. This is presumably because the early
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phase of the oxaliplatin effect had already occurred and the
tissue had entered the unresponsive late phase described above.
To see, therefore, whether the changes were dependent on
nerve conduction, we tested the effects of the Naþ channel
blocker, TTX (1 mM). When TTX was applied before
oxaliplatin, no multiple EPPs or trains were elicited by phrenic
nerve stimulation (as expected since TTX blocks nerve
conduction), and the oxaliplatin-induced increase in MEPP
frequency was also prevented (Figure 2c; Table 2). Similarly,
if TTX was applied after oxaliplatin-induced multiple EPPs
had occurred, the subsequent increase in MEPP frequency was
prevented (Table 2). These findings, combined with those
described above (Figure 2a), indicate that nerve conduction is
required for oxaliplatin to achieve an effect on spontaneous
activity, but any of the processes between the initiation of the
action potential by nerve stimulation and the release of
transmitter from the neuromuscular junction could be
involved.
Pharmacological investigation of potential oxaliplatin
targets in mouse diaphragm
Kþ channels We tried various drugs to determine whether
they either blocked or reproduced the effect of oxaliplatin. We
started by looking at Kþ channels because their blockade can
lead to motor nerve hyperexcitability. Apamin (10 mM) is
a known inhibitor of small conductance Ca2þ -activated Kþ
channels (SK channels) (Carignani et al., 2002) which are
present at the neuromuscular junction and are thought to play
a role in after-hyperpolarisation of the motor nerve terminal
(Roncarati et al., 2001). Apamin did not replicate the effects
of oxaliplatin (Table 3 and Figure 3a, n¼ 5) and had no
significant effects on MEPP amplitude or frequency, or EPP
amplitude.
4-AP (0.3mM) an inhibitor of delayed rectifier voltage-
activated Kþ channels at the neuromuscular junction (Thom-
sen & Wilson, 1983) also failed to replicate the multiple EPPs
elicited by oxaliplatin. However, this treatment significantly
increased EPP amplitude and delayed repolarisation, such that
EPP area was significantly increased compared to control
(406.4742.1 vs 135.877.5mVms, ne¼ 16 and 54, np¼ 5,
respectively) (Figure 3b). MEPP amplitude was not signifi-
cantly increased, when measured between periods of stimula-
tion (Figure 3b; Table 3), but increased MEPP frequency
occurred during the period immediately following stimulation.
Since neither of these drugs caused oxaliplatin-like effects, it is
likely that neither SK channels nor delayed rectifier Kþ
channels are the targets for oxaliplatin at the neuromuscular
junction.
Naþ channels The effects of TTX described earlier, showed
that oxaliplatin has no effect in the absence of a stimulation-
induced action potential. Carbamazepine, a drug used
clinically to treat some forms of temporal lobe epilepsy and
trigeminal neuralgia, acts by delaying the recovery of Naþ
channels from the inactivated state, thus decreasing the
availability of Naþ channels (Wang et al., 2002; Yang &
Kuo, 2002). In the mouse diaphragm, carbamazepine (0.3mM)
reduced MEPP and EPP amplitudes by 16.1 and 21.6% (after
about 20min incubation), respectively, from preincubation
values (Table 3). The decay of both MEPPs and EPPs were
prolonged and were fitted by two exponential decay functions
(Figure 3c). Addition of oxaliplatin in the presence of
carbamazepine did not lead to multiple EPPs or to an increase
in MEPP frequency (Table 3), while EPP and MEPP
amplitudes continued to decrease. During continued exposure
to carbamazepine the stimulus required to evoke an EPP
increased and there was an evident delay between the stimulus
artefact and the evoked response (Figure 3c and d); at some
endplates no EPP could be evoked, even at the maximum
stimulus voltage. These results indicate that carbamazepine
does protect the motor nerve terminal against the effects of
oxaliplatin at this concentration, but has the potential to
reduce the efficacy of neuromuscular transmission by its effects
on MEPP and EPP amplitudes. However, lower therapeutic
doses of B25 mM may preclude effects on MEPP and EPP
amplitude. These findings confirm that the effect of oxaliplatin
is crucially dependent on normal Naþ channel function, and is
unlikely to be due to an independent effect on motor nerve
excitability.
Table 1 Effects of oxaliplatin on spontaneous and evoked potential characteristics in mouse hemidiaphragm
Treatment Vehicle
control
Oxaliplatin (0.5mM) Oxalic acid
(0.5mM)
Time after intervention when recording
made
Between 5
and 71min
Between 27 and 40min
Multiple EPPs only
Between 40
and 50min
Between 51
and 80min
Between 35
and 82min
EPP amplitude (mV) 29.0870.80 29.8374.10 F F 27.3471.15
% Of preincubation 91 97 F F 97
MEPP amplitude (mV) 1.1870.04 1.0670.12 F F 1.1670.04
% Of preincubation 88 81 F F 101
MEPP frequency (detected, Hz) 0.8470.05 1.0770.20 F F 1.1870.10
% Of preincubation 87 86 F F 93
MEPP frequency (direct, Hz) 1.0770.08 1.3370.31 7.7473.12a 32.1077.49a 1.4770.13
ne¼ 19 ne¼ 7 ne¼ 19
% Of preincubation 73 100 784 3251 106
Number of endplates (ne) 55 9–13 17 19 41
Number of preparations 4 5 4 4 4
% Of preincubation: comparison with mean of three to five endplates per preparation measured before interventions began.
MEPP frequency (detected): MEPP frequency determined by measurement of interval between detected events.
MEPP frequency (direct): MEPP frequency determined by counting events during time course recording.
Multiple EPPs only: Only measurements from endplates with observed multiple EPP were included.
aDenotes a significant difference from vehicle with a P-value o0.05.
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b-pompilidotoxin, isolated from the venom of the solitary
wasp, acts on Naþ channels to delay entry into the inactivated
state (Sahara et al., 2000). This class of toxin has also been
shown to induce repetitive action potential firing in lobster
walking leg preparation (Sahara et al., 2000) and can
differentiate between rat cardiac and neuronal Naþ channels
(Kinoshita et al., 2001). In the mouse diaphragm,
b-pompilidotoxin (0.1mM) induced multiple EPPs resulting
from a single stimulus within 5min of application (Figure 4a).
There was no significant reduction in either MEPP or EPP
amplitude compared with preincubation recordings from the
same preparation. Multiple EPPs induced by b-pompilidotoxin
had two different characteristics: the majority were similar to
the late stage oxaliplatin-induced multiple EPPs (Figure 4ai),
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Figure 1 Oxaliplatin induces multiple EPPs in response to a single stimulation and increases MEPP frequency. Example traces of
(a) control, (b) early effect (c) late effect of 500 mM oxaliplatin on mouse phrenic nerve/hemidiaphragm preparation. (ai) Evoked
potentials at a low temporal resolution, (aii) single EPPs signal averaged from 30 consecutive potentials, (aiii) single spontaneous
MEPP record, signal averaged from 30 detected events. (bi) Low temporal resolution EPPs 39min after application of oxaliplatin,
on some occasions a single stimulus evoked multiple EPPs. (bii) Example of a multiple EPP from a single stimulus, typical of an
early oxaliplatin effect. (biii) Signal averaged MEPP at 34min oxaliplatin exposure. (ci) Repeated trains of EPPs following single
stimuli at 59min oxaliplatin exposure, typical of a late effect. (cii) An example of a sustained train of excitation following a single
stimulus, recorded 75min after oxaliplatin exposure. (ciii) Multiple overlapping MEPP activity observed between stimuli after
75min oxaliplatin exposure. (d) Changes in MEPP frequency during exposure to H2O vehicle (star, n¼ 4 preparations), or 500 mM
oxaliplatin (circle, n¼ 4). For each treatment group and each preparation, three to four preincubation recordings were made and the
mean7s.e.m. are displayed, labelled preincubation on x-axis. Time on x-axis indicates time after addition of vehicle or oxaliplatin.
Oxaliplatin MEPP frequency data were directly counted from continuous records. Vehicle MEPP frequency data was either
calculated from interval between detected events (np¼ 3) or counted from continuous records (np¼ 1).
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but some were associated with substantial MEPP release after
the initial EPP, without further EPPs being induced (Figure
4aii). These two phenomena could be seen in the same
endplate, separated by only a few stimuli (Figure 4b). There
was no increase in MEPP frequency between stimuli, in those
endplates that displayed multiple EPPs over the period studied
(up to 23min), see Figure 4c. It is interesting to note that from
the time of the initial effect only 55% of endplates studied had
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Figure 2 Oxaliplatin has no effect when muscle is not stimulated. (a) During oxaliplatin treatment the muscle was not stimulated
and MEPP frequency was directly assessed from continuous records (n¼ 4). Three to four endplates were studied pretreatment and
the mean7s.e.m. plotted as preincubation. An example of MEPP activity after 80min is shown in (bi), at this time the muscle was
subjected to a single stimulus, while in the maintained presence of oxaliplatin, and the resultant massive increase in MEPP activity is
shown in (bii) 8 s after the single stimulus. (c) Neuronal Na-channels were blocked by TTX (1 mM), MEPP frequency was directly
assessed from continuous records (n¼ 4). Three to four endplates were studied pretreatment and the mean7s.e.m. plotted as
preincubation, the effect of TTX alone was assessed and the mean7s.e.m. plotted as TTX. Between each assessment of MEPP
frequency the phrenic nerve was stimulated for 1min at 1Hz.
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Table 2 Nerve conduction required for increased MEPP frequency
Treatment Oxaliplatin (0.5mM) no
stimulation
Oxaliplatin (0.5mM) TTX
(1 mM) pretreatment
Oxaliplatin (0.5mM) TTX
(1 mM) post-treatmenta
Period of measurement Between 36 and 82min Between 38 and 93min Between 5 and 33min after
addition of TTX
MEPP frequency (direct, Hz) 1.0070.07 0.8070.05 1.0370.17
Number of endplates 37 39 22
Number of preparations 4 4 4
MEPP frequency (detected): MEPP frequency determined by measurement of interval between detected events.
aTTX (1mM) added after 50.573.7min incubation with oxaliplatin (0.5mM), in all preparations multiple EPPs had been observed in
several endplates.
Apamin
4-AP
Carbamazepine
0.
5 
m
V
10 ms
Carbamazepine plus oxaliplatin (69 min)
10
 m
V
10 ms
a
b
c
d
Figure 3 Pharmacological investigation of oxaliplatin effect. Example traces of signal averaged EPPs and MEPPs (up to 30
records) are shown for each treatment (solid lines), for reference a control trace is aligned for each example (broken line).
(a) Apamin (10 mM) after 61min incubation. (b) 4-AP (0.3mM) after 6min incubation. (c) Carbamazepine (0.3mM) after 14min
incubation. (d) Carbamazepine (0.3mM) and oxaliplatin (0.5mM) after 69min oxaliplatin incubation.
R.G. Webster et al Oxaliplatin-induced hyperexcitability at NMJ 1033
British Journal of Pharmacology vol 146 (7)
multiple EPPs with b-pompilidotoxin. This compares with
87% of endplates showing multiple EPPs after the start of
the oxaliplatin-induced disruption. Overall, the effects of
b-pompilidotoxin were more variable, but the toxin did
reproduce some of the changes seen with oxaliplatin.
Effects of oxaliplatin on autonomic transmission
in the mouse vas deferens
The vas deferens preparation is particularly suitable for testing
the effects of drugs on autonomic transmission, and allows one
to look for possible effects on intra-terminal Ca2þ . Sponta-
neous sEJPs were measured with standard intracellular
electrode recording techniques. After 20–30min in oxaliplatin
(0.5mM) the frequency of sEJPs began to increase, with an
average 3.4-fold increase (from a resting frequency of
0.1170.03 s1; np¼ 7; Figure 5a) during the period between
30 and 60min. Many of the sEJPs in the presence of
oxaliplatin occurred in bursts. In each of the seven prepara-
tions there was a marked increase in the frequency of bursts of
sEJPs (0.04270.015 s1; a 60-fold increase over controls;
Figure 5b and c). Indeed, in four out of seven preparations,
no bursts were detected in the controls.
To determine whether bursts of spontaneous transmitter
release were generated by bursts of nerve terminal action
potentials, TTX was applied. TTX (100 nM) abolished all
EJPs (Figure 5e) in normal tissue, confirming that action
potential generation was abolished. Upon the addition of
oxaliplatin (0.5mM), still in the presence of TTX, there was no
increase in the frequency of sEJPs or bursts of sEJPs
(Figure 5e; n¼ 3), suggesting that, as in the diaphragm pre-
paration, the oxaliplatin effect was dependent on Naþ channel
activity.
Carbamazepine (0.3mM) reduced the amplitude of EJPs by
55712% (n¼ 5; Po0.05). However, the subsequent applica-
tion of oxaliplatin (0.5mM) in the continued presence of
carbamazepine (0.3mM) resulted in no further change in the
amplitude of EJPs (þ 4723%) (Figure 5f). Both the rate of
spontaneous EJPs (0.1870.05 s1) and bursts of sEJPs
(0.00970.005 s1) were significantly lower than when oxali-
platin alone was present (Po0.05 using an unpaired t-test).
There was no change in the smooth muscle resting membrane
potential (171mV).
Confocal Ca2þ imaging
It has been suggested that oxaliplatin might act by altering
nerve terminal Ca2þ regulation (Grolleau et al., 2001). We
studied the effect of oxaliplatin on Ca2þ concentration in
nerve terminal varicosities ([Ca2þ ]v), both at rest and following
nerve stimulation. Following a nerve terminal action potential
the [Ca2þ ]v rose rapidly (Figure 6a), before recovering to its
resting concentration over a period of seconds as previously
described (Brain & Bennett, 1997). Oxaliplatin (0.5mM) had
no effect on the amplitude of the residual [Ca2þ ]v transient
following either single nerve terminal action potentials
(þ 1.370.8%; number of nerve terminal varicosities, nv¼ 18;
np¼ 5) or trains of five action potentials at 5Hz (7710%;
nv¼ 14; np¼ 4; Figure 6b).
In order to investigate cytoplasmic Ca2þ buffering and
sequestration mechanisms, the kinetics of [Ca2þ ]v recovery
following trains of five action potentials at 5Hz was
investigated. There was no change in the time course of the
first (and dominant) component of [Ca2þ ]v recovery
(Figure 6c; 0.4170.07 s in the control compared to
0.4370.06 s in oxaliplatin). Significant spontaneous contrac-
tion and subsequent movement in the presence of oxaliplatin
meant that the slower component of recovery (previously
described with a time course of about 4 s) could not be
adequately assessed.
In the presence of oxaliplatin, spontaneous bursts of rapid
whole nerve terminal Ca2þ transients (consistent with sponta-
neous action potentials) were observed in two out of five
preparations. In one of these preparations, the action potential
bursts were associated with local tissue contraction, suggesting
that they had initiated local transmitter release.
Table 3 Effects of channel modulators on neurotransmission in mouse hemidiaphragm
Treatment Apamin (10mM) 4-AP (0.3mM) Carbamazepine
(0.3mM)
Carbamazepine
(0.3mM) then
oxaliplatin (0.5mM)
b-pompilidotoxin
(0.1mM)
Period of measurement Between 10 and
66min
Between 5 and
34min
Between 5 and
19min
Between 35 and 82min
after addition of
oxaliplatin
Between 2 and
40min multiple
EPPs only
EPP amplitude (mV) 30.8371.05 38.7072.43** 22.4772.03* 16.9770.92** 24.8573.11
% Of preincubation 103 138 78 59 86
MEPP amplitude (mV) 1.1870.04 1.2270.07 1.0970.07 0.8770.03* 0.9770.11
% Of preincubation 101 108 84 67 84
MEPP frequency (detected, Hz) 0.9370.05 2.3070.19** 0.6970.04 0.9370.14 2.0170.47**
% Of preincubation 87 205 62 84 220
MEPP frequency (direct, Hz) 1.1670.08 2.1970.18** F F 1.0370.14
ne¼ 29 ne¼ 34 ne¼ 10
Number of endplates (ne) 66 31 14–18 31–41 8–10
Number of preparations. 5 5 4 4 4
% Of preincubation: comparison with mean of three to five endplates per preparation measured before interventions began.
MEPP frequency (detected): MEPP frequency determined by measurement of interval between detected events.
MEPP frequency (direct): MEPP frequency determined by counting events during time course recording.
Multiple EPPs only: Only measurements from endplates with observed multiple EPP were included.
* and ** denote a significant difference from vehicle with a P-value o0.05 or 0.01, respectively.
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Discussion
Although the neurotoxic effects of oxaliplatin have been
recognised for some time, there have been no previous studies
on the tissue preparation that represents one of the main target
tissues in vivo. Here we show that oxaliplatin increased both
evoked and spontaneous neurotransmitter release in the motor
nerve terminal of the phrenic nerve hemidiaphragm prepara-
tion, and these effects did not occur if the preparation was first
blocked by TTX. Indeed, slowing Naþ channel recovery from
inactivation with the antiepileptic carbamazepine substantially
reduced the effects of oxaliplatin. Interestingly, the effects of
oxaliplatin were replicated to a large extent by the wasp toxin,
b-pompilidotoxin (Sahara et al., 2000). b-pompilidotoxin,
examined for the first time at the mammalian neuromuscular
junction, produced repetitive activity and some hyperexcit-
ability, probably via a mechanism which delays entry of Naþ
channels into an inactivated state.
These observations suggest that oxaliplatin has an action on
the kinetics of voltage-gated Naþ channels. There are many
different sites of action of sodium channel effectors and
neurotoxin sites 3, 4 and 5 could be involved in the effects of
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Figure 4 b-pompilidotoxin mimics some of the actions of oxaliplatin. (ai) Example trace of b-pompilidotoxin induced multiple
EPPs following stimulation. (aii) Example trace of an EPP associated with elevated MEPP activity in presence of b-pompilidotoxin.
(b) Example of two variations of b-pompilidotoxin-induced EPP abnormalities within one continuous trace recorded from a single
endplate, 33min after toxin application. (c) MEPP frequency during b-pompilidotoxin incubation (n¼ 4), three to four endplates
were studied pretreatment in each preparation and the mean7s.e.m. plotted as preincubation (error bars are contained within the
symbol). Triangles are MEPP frequencies calculated from the interval between detected events, circles are directly measured in
continuous records, each symbol represents an individual endplate.
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oxaliplatin (Cestele & Catterall, 2000). Neurotoxins active at
these sites can produce increases in spontaneous activity in
motor nerves similar to b-pompilidotoxin, via shifts in voltage
dependence of activation and/or prolonging Naþ channel
openings (Oliveira et al., 1989; Molgo et al., 1990; Gilles et al.,
2000). For example, oxaliplatin was found to have type-3-like
actions in cultured dorsal root ganglia neurons, where slowed
Naþ channel inactivation kinetics was accompanied by a shift
in the voltage dependence of activation (Adelsberger et al.,
2000). While in cultured dorsal unpaired median neurons of
the cockroach, oxaliplatin reduced the peak Naþ current, a
type-4 action (Grolleau et al., 2001), and in a third tissue,
cultured hippocampal neurons, oxaliplatin had no effect
(Adelsberger et al., 2000). These differences probably reflect
differential expression of Naþ channel subtypes in these
different tissues. Given the variation in effects in different
tissues, and since b-pompilidotoxin does not fully replicate the
actions of oxaliplatin, the effects of oxaliplatin may be due to
alteration in either the voltage dependence of activation or the
kinetics of inactivation.
In fact, the results were partially different in the vas
deferens. In this preparation, oxaliplatin initiated bursts of
sEJPs, reflecting bursts of transmitter release from sympathetic
nerves. These bursts of transmitter release are probably
generated by bursts of nerve terminal action potentials as they
did not occur in the presence of TTX, and oxaliplatin-induced
bursts of nerve terminal action potentials were observed during
confocal Ca2þ imaging. These results are consistent with a
direct effect of oxaliplatin on voltage-gated Naþ channels on
the nerve varicosities. At the mouse motor nerve terminal,
there are no voltage-gated Naþ channels and the oxaliplatin
effect on EPPs and spontaneous release are likely, instead,
to be dependent on the passive depolarisation caused by
prolonged or repetitive motor nerve action potentials. Previous
work had suggested that alteration in intracellular Ca2þ
regulation by oxaliplatin was responsible for the modification
of voltage-gated Naþ channel activity (Grolleau et al., 2001).
Our results, showing that autonomic hyperexcitability oc-
curred in the vas deferens preparation in the absence of
changes in Ca2þ handling, do not support a role for calcium
regulation in the effects of oxaliplatin in this tissue. Moreover,
carbamazepine both protected autonomic nerves from a
decrement in evoked transmitter release and reduced the rate
of spontaneous transmitter release, consistent with an effect
of oxaliplatin on Naþ channel kinetics. The decline in the
amplitude of the EPP and EJP induced by carbamazepine
alone may be due to a partial Ca2þ channel block (Elliott,
1990).
This study addressed the acute hyperexcitability associated
with oxaliplatin therapy (Lehky et al., 2004) rather than the
axonal neuropathy and cell death that follows chronic
treatment and appears similar to that of other platinum-based
chemotherapeutic agents. We used a concentration of oxali-
platin that is used in therapeutic infusions, and within the
range used in other studies of oxaliplatin neurotoxicity in
tissues and cell-based assays (25–250mM; Adelsberger et al.,
2000; and 100–500 mM; Grolleau et al., 2001). As in other
studies (Adelsberger et al., 2000) we found similar effects with
lower concentrations, but they took longer to develop. The
concentration we used was higher than that achieved in
the plasma of treated patients but may be similar to that in the
tissues. Pharmacokinetic studies of oxaliplatin (130mg/m2
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Figure 5 Oxaliplatin reduces the amplitude of EJPs and increases sEJP frequency in the vas deferens. (a) Shows a representative
trace of the membrane potential recorded in the mouse vas deferens. Field stimuli were applied every 3 s (arrows) and result in a
stimulus artefact (downward deflection) and excitatory junction potential (depolarisation). sEJPs, which report the spontaneous
release of ATP, are occasionally detected. After 40min in oxaliplatin (0.5mM); (b) the amplitude of EJPs was lower and bursts of
sEJPs were recorded. The first few seconds of this recording have been magnified in (c), and the frequency of sEJPs over time is
shown in (d), with the data collected into 5min bins. Pretreatment with either TTX (e) or carbamazepine (f) prevents oxaliplatin’s
effect on sEJP frequency. In parts (d), (e) and (f) data (collected into 5min bins) from representative experiments are plotted.
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oxaliplatin as a 4 h infusion) revealed a peak concentration of
free platin of about 1600 ng/ml (or 5.6 mM; Kern et al., 1999),
with a terminal half-life of 27 h, implying that the body is
exposed to oxaliplatin for a significant length of time.
Moreover, oxaliplatin’s large volume of distribution (free
platin, 350 l; protein-bound platin 180 l) implies that there are
areas outside the circulation in which oxaliplatin accumulates
at much higher concentrations. Intracellular accumulation has
been confirmed, at least in erythrocytes (Pendyala & Creaven,
1993) and human ovarian carcinoma cell lines (Pendyala et al.,
1995).
The reason for the delay in the effects of oxaliplatin on
evoked transmitter release is unclear. Oxaliplatin is taken up
by cells and metabolised to various platinum biotransforma-
tion products, including 1,2-diaminocyclohexane-platinum.
This compound enters the nucleus where it acts as an alkylating
agent to form inter- and intracross links within DNA, leading
eventually to apoptosis (Wiseman et al., 1999; Misset et al.,
2000). The delayed results could be because of delayed entry of
oxaliplatin into the nerve terminals, where it might act to alter
calcium release from intracellular stores, but the lack of effect
on calcium release in the presence of TTX argues against this.
Another oxaliplatin breakdown product is oxalate. Oxalate
increases the uptake of Ca2þ into intracellular stores (Grover &
Kwan, 1984); oxalate enters the ER and then binds Ca2þ in the
ER lumen (Waldron et al., 1995). A French group used
infusions of calcium gluconate and magnesium sulphate before
and after oxaliplatin as oxalate chelators and suggested that
Ca/Mg infusions reduced incidence and intensity of acute
oxaliplatin-induced symptoms and might delay cumulative
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Figure 6 Confocal nerve terminal Ca2þ imaging in the presence of oxaliplatin. (a) Shows consecutive confocal images of part of a
nerve terminal in the mouse vas deferens filled with the Ca2þ indicator Oregon-BAPA-1. A nerve terminal varicosity is marked with
an arrow on the first frame. Images were acquired every 0.214 s and field stimuli (sufficient to induce a single nerve terminal action
potential) applied at the #. This results in an increase in the fluorescent intensity, indicating an increase in Ca2þ concentration
within every nerve terminal varicosity ([Ca2þ ]v). Upon cessation of the stimulus train, the [Ca
2þ ]v returns towards its resting
concentration. (b) Shows the same site 40min after the application of oxaliplatin. The change in the fluorescent signal from the
varicosity marked with the arrow is quantified in (c). This figure shows the relative change in fluorescence (DF/F), averaged over
eight recordings taken 3min apart, in absence and then presence of oxaliplatin. The error bars show the s.e.m. Oxaliplatin had no
significant effect on the stimulation-evoked change in [Ca2þ ]v.
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neuropathy (Gamelin et al., 2004). However, the lack of
evidence for a change in Ca2þ regulation in the nerve terminal
following action potential-induced Ca2þ influx in the vas
deferens, makes it unlikely that oxalate release is an important
mechanism of action of the drug, at least in autonomic ter-
minals. In addition, we saw no effect of 0.5mM oxalic acid on
neurotransmission in the mouse hemidiaphragm preparation.
The role of defects on Naþ and Kþ channels in neurological
diseases is well recognised. Slowing of Naþ channel inactiva-
tion kinetics has been implicated in many of the myotonias
(Cannon, 1997), diseases which cause periodic muscle stiffness
and/or weakness. In these cases, the altered kinetics of the
muscle Naþ channels allow greater Naþ current to pass and
result in repetitive firing. It is also interesting to note that the
altered kinetics of this mutant channel is exacerbated by cold
(Bouhours et al., 2004), similar to the exacerbation of sensory
signs with oxaliplatin-induced neurotoxicity. Reduced Kþ
channel activity, due to genetic mutations, autoantibodies,
drugs or toxins, can also cause similar symptoms in nerve or
muscle diseases (Hart et al., 1997; Kinali et al., 2004). Indeed, a
previous clinical study of oxaliplatin-induced hyperexcitability
and neuropathy described symptoms reminiscent of
neuromyotonia (Lehky et al., 2004), a condition that results
from impairment of Kþ channel-dependent membrane repo-
larisation and is often caused by autoantibodies to Kþ
channels (Newsom-Davis, 2004). However, the lack of similar
oxaliplatin-like effects with Kþ channel blockade suggests that
reduction in Kþ channel function is unlikely to be the cause of
hyperexcitability in the hemidiaphragm preparation.
In the tissues we examined, therefore, the most likely
mechanism of oxaliplatin neurotoxicity is a direct effect on
voltage-gated Naþ channels rather than an effect on Kþ
channels or nerve terminal Ca2þ regulation. Although no
effect of carbamazepine was seen in one study (Wilson et al.,
2002), both carbamazepine and gabapentin, which prolong
Naþ channel inactivation, have been used clinically to reduce
the neurotoxic effects of oxaliplatin (Lersch et al., 2002). Our
results suggest that targeting Naþ channels will continue to
provide the best approach to counteract the acute neurotoxic
effects of oxaliplatin.
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